Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,379.09 -45.76 -0.28%
S&P 500 1,861.21 -1.10 -0.06%
NASDAQ 4,073.90 -12.32 -0.30%
Ticker Volume Price Price Delta
STOXX 50 3,150.39 11.13 0.35%
FTSE 100 6,612.24 28.07 0.43%
DAX 9,395.56 77.74 0.83%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

The Zacks Analyst Blog Highlights:RocheHoldings Ltd, GlaxoSmithKline, Ford, General Motors Companyand Nissan Motor Co



 The Zacks Analyst Blog Highlights:RocheHoldings Ltd, GlaxoSmithKline, Ford,
                  General Motors Companyand Nissan Motor Co

PR Newswire

CHICAGO, Nov. 13, 2012

CHICAGO, Nov. 13, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Roche Holdings Ltd. (RHHBY),
GlaxoSmithKline (GSK), Ford (F), General Motors Company (GM) and Nissan Motor
Co. (NSANY).

(Logo:  http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Today, Zacks is promoting its ''Buy'' stock recommendations. Four daily picks
are offered free.

Here are highlights from Tuesday's Analyst Blog:

Priority Review for Roche Candidate

Roche Holdings Ltd. (RHHBY) recently announced that it has received priority
review for its oncology candidate, trastuzumab emtansine (T-DM1) in the US.

In August 2012, Roche had filed a Biologics License Application (BLA) for
trastuzumab emtansine for the treatment of HER2-positive unresectable locally
advanced or metastatic breast cancer patients who have received prior
treatment with Herceptin (trastuzumab) and taxane-based chemotherapy. Roche
has partnered with ImmunoGen, Inc. (IMGN) for the candidate.

Priority review status means that the US Food and Drug Administration (FDA)
will review the marketing application within 6 months instead of the standard
10 months. A response should be out by February 26, 2013.

The approval of trastuzumab emtansine will strengthen Roche's HER2 franchise.
Last month, Roche had announced additional results from its phase III EMILIA
study, which was conducted with trastuzumab emtansine. The study compared
trastuzumab emtansine to GlaxoSmithKline's (GSK) Tykerb (lapatinib) along with
Xeloda (capecitabine) in HER2-positive unresectable locally advanced or
metastatic breast cancer patients who were previously treated with Herceptin
and taxane chemotherapy.

Results showed that patients who were treated with trastuzumab emtansine
survived longer (risk of death was reduced by 32%) than those who were treated
with the combination of lapatinib and Xeloda. Median overall survival was
higher in the trastuzumab emtansine arm compared to patients receiving
lapatinib and Xeloda (30.9 months vs. 25.1 months).

Roche also submitted a marketing authorization application for trastuzumab
emtansine to the European Medicines Agency (EMA) for use in
treatment-experienced HER2-positive metastatic breast cancer patients.

Our Recommendation

Roche carries a Zacks #2 Rank (Buy rating) in the short run. We are pleased
with the company's progress with its oncology candidates. In the fourth
quarter of 2012, Roche plans to initiate a phase III trial evaluating the
combination of the MEK inhibitor (RG 7421) and Zelboraf BRAF mutation-positive
metastatic melanoma. Successful development and commercialization of these
products will aid Roche's top line.

Ford Builds New Plug-In in Michigan

Ford Motor Co. (F) started producing its new plug-in hybrid C-Max Energi at
its retooled Michigan assembly plant that is capable of manufacturing vehicles
based on multiple platforms. The automaker overhauled the 55-year-old plant in
2009 by spending $550 million that used to roll out Expedition and Lincoln
Navigator full-size SUVs.

According to Ford, the Michigan plant is the only existing plant in the world
that produces gas-powered, hybrid, plug-in hybrid and electric cars all on the
same production line due to its advanced retooling and trained workers capable
of producing a wider range of models. Currently, the plant can produce five
body styles on two platforms, including gas-powered versions of the Ford Focus
compact car.

Unlike its peers, Ford has undertaken "One Manufacturing" strategy, which aims
at producing multiple models from plants across the world in order to save
production costs and fast adaptation to changes in consumer tastes. In
contrast, Ford's cross town rival General Motors Company (GM) and Japan's
Nissan Motor Co. (NSANY) produce their Chevrolet Volt and Nissan Leaf,
respectively, at plants having standalone platforms.

According to Jim Tetreault – head of manufacturing in North America, this
flexible manufacturing style becomes possible, especially at plants that
produce cars, sedans and crossovers and not trucks, which have different
designing requirements. Ford anticipates producing 4.5 models at each of its
plants by 2015, up from 3.6 models currently.

Apart from Michigan, Ford's plant in Oakville, Ontario can deliver three body
styles on two platforms and in Louisville, Kentucky, six styles on three
platforms. The company now intends to make its other plants capable of
producing vehicles based on multiple platforms; however, doing so, the company
might face challenges in modifying fuel economy and safety requirements.

Ford, a Zacks #3 Rank (Hold) company, posted a 17.6% rise in earnings per
share to 40 cents in the third quarter of the year from 34 cents a year ago,
driven by impressive results in its North American operation and, to some
extent, its Asian operation. With this, the company has also beaten the Zacks
Consensus Estimate by 10 cents per share. Total profit rose 15.6% to $1.6
billion from $1.4 billion a year ago.

However, total revenue in the quarter slid 3.0% to $32.1 billion due to lower
revenues in South America, Europe and Financial Services operations that
offset the marginal improvement in revenues in North America and Asia.
However, revenues were higher than the Zacks Consensus Estimate of $31.0
billion for the quarter.

Today, Zacks is promoting its ''Buy'' stock recommendations. Four daily picks
are offered free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978. The later formation of the Zacks Rank, a proprietary stock picking
system; continues to outperform the market by nearly a 3 to 1 margin. The best
way to unlock the profitable stock recommendations and market insights of
Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED
to be worth your time! Register for your free subscription to Profit from the
Pros.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment
is the potential for loss. This material is being provided for informational
purposes only and nothing herein constitutes investment, legal, accounting or
tax advice, or a recommendation to buy, sell or hold a security. No
recommendation or advice is being given as to whether any investment is
suitable for a particular investor. It should not be assumed that any
investments in securities, companies, sectors or markets identified and
described were or will be profitable. All information is current as of the
date of herein and is subject to change without notice. Any views or opinions
expressed may not reflect those of the firm as a whole. Zacks Investment
Research does not engage in investment banking, brokerage, market making or
asset management activities of any securities. Visit
http://www.zacks.com/performance for information about the performance numbers
displayed in this press release.

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement